Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag for Vorinostat-induced Thrombocytopenia in Lymphoma
NCT01500538Phase 2
Key facts
- Status
- Terminated
- Start
- Oct 2012
- Primary completion
- May 2013
- Countries
- 1
- Sponsor
- Peter MacCallum Cancer Centre
- Modality
- Small Molecules
- Drugs
- eltrombopag
- Conditions
- Thrombocytopenia
01
Overview
Phase 2, open-label trial of eltrombopag in Thrombocytopenia, sponsored by Peter MacCallum Cancer Centre. Started Oct 2012; status: terminated.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Registry description
Vorinostat is a drug (Histone Deacetylase Inhibitor \[HDACi\]) administered orally that has been approved in United States for the patients with cutaneous Tcell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.
In the early period of treatment with vorinostat, some patients may experience low platelet counts. Therefore this study will be examining the combination of these two medications (Vorinostat and eltrombopag) to assess if eltrombopag can overcome the low platelets during treatment with vorinostat.
Eltrombopag is a drug…
Beyond the preview
Go deeper on NCT01500538.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01500538.